#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malformation venous Biotinidase deficiency Ewing's sarcoma recurrent Leukodystrophy Acute graft versus host disease in skin Peripheral primitive neuroectodermal tumour of soft tissue Cutaneous T-cell lymphoma refractory Cognitive disorder Familial hypertriglyceridaemia Amyotrophic lateral sclerosis gene carrier Alagille syndrome Hypersomnia Lymphangioma Toxic epidermal necrolysis Prostate cancer More trials…

    Learn about Rare Diseases

    Retinitis pigmentosa – Diagnostics Marfan’s syndrome Alport’s syndrome Hereditary ataxia – Trials in Disease Osteosarcoma Lymphangiosarcoma – Life with Disease Richter’s syndrome – Basic Information Rosai-Dorfman syndrome – Basic Information Haemophilia B with anti factor IX – Treatment Metachromatic leukodystrophy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lib-01 Monohydrate Topotecan Hydrochloride AZD0120 Interleukin-1 LVT-001 Betamethasone Acetate ALE.P03 Disulfiram Anselamimab Losmapimod Procarbazine Cefalexin RNMB3 Trazodone Linagliptin Hdp-101 Methohexital Sodium Magnesium Citrate Azithromycin Sodium Nitrite More therapies…

    Learn about Your Condition

    Retinitis pigmentosa Procedural hypotension Bacteraemia Acarodermatitis Vulvovaginal candidiasis Pseudoxanthoma elasticum Palmoplantar pustulosis Prostate cancer recurrent Osteomyelitis acute Mesothelioma Endocrine disorder Crigler-Najjar syndrome Carotid artery stenosis Acoustic neuroma Stevens-Johnson syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Systemic scleroderma

  • Study on Mesenchymal Stem Cells for Patients with Systemic Sclerosis and Digital Ulcers

    Recruiting

    2 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Human Mesenchymal Stem Cells
    The Netherlands

  • A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

    Recruiting

    4 1 1
    Investigated Drugs:
    • Kyv-101
    Germany

  • Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

    Recruiting

    2 1
    Investigated Diseases:
    • Interstitial lung disease
    • Systemic scleroderma
    Investigated Drugs:
    • Amlitelimab
    • Bi 1015550
    Austria Belgium Denmark France Germany Italy +5

  • A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

    Not yet recruiting

    3 1
    Investigated Drugs:
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    • Bi 1015550
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Obinutuzumab
    France

  • Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • Glucose Monohydrate
    • Sodium Chloride
    France Italy The Netherlands Poland Romania Spain
Previous Page
1 2 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!